Promoter holding
64.27%
CR
Cliantha Research Limited - Due diligence report
A 360° intelligence report on Cliantha Research: trust score, financial health, credit view, compliance, directors, growth and distress sign…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Cliantha Research — 360° Intelligence Report
Generated from MCA filings & public records81/100
Trust Score
Low Risk
Cliantha Research is assessed as Low Risk with a Trust Score of 81/100. Cliantha Research is an active public limited indian non-government company incorporated in 2004, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 17 Jul 2026 from the latest processed filings. Cliantha Research Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
81/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
86/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
30/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 2 open (125.00 cr) · 2 satisfied (9.25 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| The Hongkong And Shanghai Banking Corporation Limited | 2 | 48.0 cr |
| Standard Chartered Bank | 1 | 48.0 cr |
| Icici Bank Limited | 1 | 48.0 cr |
Compliance Score: 86/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 2 court forum(s).
- 2 active GST registration(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 30/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| MANUBHAI KHODIDAS PATEL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MUKESH MANGALBHAI PATEL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NILIMA ARUN KSHIRSAGAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Rajiv Vikrambhai Kamani | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| YOGENDRA KUMAR GUPTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NAVEEN SHARMA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Naveen Sharma | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 7 directors on the board.
- NAVEEN SHARMA has DIN status "Deactivated due to non-filing of DIR-3 KYC".
- 5 director exits in 3 years - high churn.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Hill Top Research Inc. | Subsidiary Company | 74.00% |
| Hill Top Research Limited | Subsidiary Company | 74.00% |
| Inflamax Research Limited | Subsidiary Company | 74.00% |
Key managerial personnel: NAVEEN SHARMA (CEO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 75 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
EPFO headcount growing - hiring signal.
Operating for 21+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
4 director exits within 2 years.
2 open charge(s) registered - assets are encumbered.
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence83/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment93/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 2 open charge(s) of 125.00 cr already registered.
- Compliance record supports lending.
Investor view84/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 2 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 15 events10 Nov 2025
Director ceased
NAVEEN SHARMA
08 Aug 2025
Director appointed
MUKESH MANGALBHAI PATEL (Additional Director)
30 Jun 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
03 Oct 2024
Director appointed
Naveen Sharma (Ceo)
29 Sep 2024
Director ceased
NILIMA ARUN KSHIRSAGAR
Director ceased
Rajiv Vikrambhai Kamani
Director ceased
YOGENDRA KUMAR GUPTA
05 Sep 2024
Director appointed
NILIMA ARUN KSHIRSAGAR (Director)
Director appointed
Rajiv Vikrambhai Kamani (Director)
Director appointed
YOGENDRA KUMAR GUPTA (Director)
Director appointed
NAVEEN SHARMA (CEO)
10 Aug 2023
Director ceased
SHILPA MUKESH PATEL
16 Jun 2021
Charge satisfied
The Hongkong And Shanghai Banking Corporation Limited
22 Jul 2020
Charge created
The Hongkong And Shanghai Banking Corporation Limited - 4.25 cr
10
Key Observations
Auto-generated from the data aboveRevenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
7 active director(s) / partner(s); review board churn before relying on management continuity.
2 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
83 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Fev | U34300DL2006PTC146790 | New Delhi, Delhi, India |
| Aurigene Pharmaceutical | U74999KA2019PLC127964 | Bangalore, Karnataka, India |
| Sabic Research & Technology Private Limited | U74110KA1998PTC080762 | Bengaluru, Karnataka, India |
| Lambda Therapeutic | U24236GJ1998PLC034883 | Ahmedabad, Gujarat, India |
| Ppd | U73100MH2004PTC144454 | Mumbai, Maharashtra, India |
| Rubicon | L73100MH1999PLC119744 | Thane, Maharashtra, India |
| Icon | U74110TN2004PTC054137 | Chennai, Tamil Nadu, India |
| Baxter International | U74999KA2017PTC109068 | Bangalore North, Karnataka, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Cliantha Research before audits and certifications: compliance score 86/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Cliantha Research: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Cliantha Research - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 81/100, distress signals and MSME payment-delay disclosures - know whether Cliantha Research pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Cliantha Research - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Cliantha Research an active company?
Cliantha Research has MCA status “Active” with a compliance score of 86/100 (Low Risk).
Is Cliantha Research financially healthy?
Cliantha Research has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Cliantha Research?
Its overall Trust Score is 81/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Cliantha Research?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 7 active director(s) are on record.
Does Cliantha Research have loans or charges against its assets?
2 open charge(s) are registered against its assets, and 2 earlier charge(s) stand satisfied.
Is Cliantha Research up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 86/100 (Low Risk).
Is it risky to lend to Cliantha Research?
Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
